ArticleOncoTargets and therapy2017
Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma.African health sciences · 2025Article
- Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma.Drugs in R&D · 2023Article
- Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report.Oncology letters · 2023Article
- Personalized Medicine in Brain Gliomas: Targeted Therapy, Patient-Derived Tumor Models (Review).Sovremennye tekhnologii v meditsine · 2023Review
- Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report.World journal of clinical cases · 2022Article
- Low-Dose Apatinib Improves the Prognosis of Patients with Recurrent High-Grade Gliomas.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option.Frontiers in pharmacology · 2022Article
- Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the VEGFR2/Nrf2 Pathway.Oxidative medicine and cellular longevity · 2022Article
- Apatinib inhibits glioma cell malignancy in patient-derived orthotopic xenograft mouse model by targeting thrombospondin 1/myosin heavy chain 9 axis.Cell death & disease · 2021Article
- Glioblastoma multiforme: a multi-omics analysis of driver genes and tumour heterogeneity.Interface focus · 2021Article
- NDUFA4L2 promotes glioblastoma progression, is associated with poor survival, and can be effectively targeted by apatinib.Cell death & disease · 2021Article
- Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports.World journal of clinical cases · 2020Article
- Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism.Saudi journal of biological sciences · 2020Article
- Influence and mechanism of lung cavitation development on antiangiogenic therapy.Translational lung cancer research · 2019Article
- Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study.OncoTargets and therapy · 2019Article
- Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review.OncoTargets and therapy · 2019Article
- Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.Medicine · 2018Article
- Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review.Oncotarget · 2018Article
- Article
- Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant glioma (MG) is a common and refractory primary tumor with a high recurrence rate. There is still a lack of effective therapy for recurrent MG (rMG). We present here two cases of refractory rMG treated using apatinib, which is a new highly selective inhibitor to VEGFR. Case 1, a 37-year-old female, was diagnosed with recurrent intracerebral high-grade glioma and failed to almost all treatments (including temozolomide, bevacizumab, nimotuzumab, reradiation, etc) during her second relapse. Case 2, a 40-year-old male, was diagnosed with recurrent glioblastoma multiforme for the third time following multiple treatments including resurgery, temozolomide and radiation. These two patients were treated with oral apatinib (500 mg daily) during their most recent relapse and experienced rapid relief of central nervous system symptoms. Case 1 achieved near complete response evaluated by magnetic resonance imaging (MRI) after 6, 12 and 20 weeks medication and had an overall survival of 27 weeks. Case 2 achieved partial response evaluated by MRI after 4 and 12 weeks medication and had a progression-free survival of 12 months. The preliminary results of these two cases indicate that apatinib has outstanding efficacy for refractory rMG. It is worthwhile to develop a Phase II clinical trial to further evaluate the efficacy and toxicity of apatinib for rMG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.